CND Life Sciences Secures $3.51M to Accelerate Breakthrough Neurodegenerative Diagnostics

CND Life Sciences is excited to announce that the company has successfully raised $3,510,000 in funding—a pivotal milestone that will further accelerate its mission to advance diagnostic innovation in neurodegenerative diseases. With a steadfast commitment to supporting patients suffering from conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, the new capital will be dedicated to expanding clinical research, enhancing laboratory capabilities, and fostering strategic collaborations with leading biopharmaceutical companies. Operating from its CLIA-certified and CAP-accredited laboratory in Scottsdale, AZ, CND Life Sciences continues to lead the way with groundbreaking diagnostic solutions, most notably through the launch of its Syn-One Test®. This first-of-its-kind diagnostic tool is designed to detect, visualize, and quantify misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers, providing a revolutionary, objective alternative to traditional, invasive diagnostic methods. By analyzing three small in-office skin biopsies provided by referring physicians, the Syn-One Test® not only offers a minimally invasive option but also significantly improves the accuracy and speed of diagnosing complex neurodegenerative conditions. The substantial funding injection will enable the company to scale up its research initiatives and technology integration, ultimately aiming to refine early intervention strategies and improve patient outcomes. As CND Life Sciences forges ahead, this investment marks a major step forward in its ongoing pursuit to blend cutting-edge science with compassionate patient care, while continuously setting new benchmarks in the field of neurological diagnostics.